Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

expertreviewby [‘mediPr]
HER2 Explorer

Hong Kong corner · Section

HER2 Explorer

Lung Cancer

For registered Hong Kong doctors
Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker AssessmentNavigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker AssessmentDue to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-1031 Jul 2025SponsoredPrevalence and role of HER2 driver mutations in cancersPrevalence and role of HER2 driver mutations in cancersApart from Human Epidermal Growth Factor Receptor 2 (HER2) gene amplification or receptor protein overexpression (discussed in Article 1 and Article 3), dysregulation of HER2 activity may also be caused by HER2 gene mutations.1 Approximately 90% of the mutations are clustered in the extracellular dimerization domain and intracellular kinase domain, with the remainder occurring within the juxtamembrane or transmembrane domains.14 Apr 2025SponsoredHER2 as a biomarker in cancers_0824HER2 as a biomarker in cancersHuman epidermal growth factor receptor-2 (HER2) is a member of the erythroblastic oncogene B (ERBB) family of transmembrane tyrosine kinase receptors that also includes epidermal growth factor receptor (EGFR, also known as HER1), and human epidermal growth factor receptors -3 and -4 (HER3, HER4).1,2 Despite being a receptor, HER2 has no known ligand, but its conformation is similar to the ligand-activated form of other ERBB family members, favoring heterodimerization with them.1,316 Jul 2024Sponsored